Tags

Type your tag names separated by a space and hit enter

Arginine vasopressin receptor antagonists (vaptans): pharmacological tools and potential therapeutic agents.
Drug Discov Today. 2010 Oct; 15(19-20):826-41.DD

Abstract

Arginine vasopressin (AVP) attracted attention as a potentially important neurohormonal mediator of the heart failure (HF) syndrome and hyponatremic states in humans because AVP influences renal handling of free water, vasoconstriction and myocyte biology through activation of V₂ and V₁(a) receptors. Current research is exploring V₂- and dual V₁(a)/V₂ receptor antagonism for the treatment of hyponatremia, as well as for the congestion and edema associated with chronic HF, because vasopressin receptor antagonists might offer benefits in comparison with conventional loop diuretics. The purpose of this review is to update the current status of experimental and clinical studies with available vasopressin receptor antagonists (conivaptan and tolvaptan) and their potential role in the treatment of HF and hyponatremia of multiple causes.

Links

Publisher Full Text

Authors+Show Affiliations

Veeraveedu PT
Department of Clinical Pharmacology, Niigata University of Pharmacy and Applied Life Sciences, Higashijima Akiha-ku, Niigata City, Japan.
Palaniyandi SS
No affiliation info available
Yamaguchi K
No affiliation info available
Komai Y
No affiliation info available
Thandavarayan RA
No affiliation info available
Sukumaran V
No affiliation info available
Watanabe K
No affiliation info available

MeSH

Antidiuretic Hormone Receptor AntagonistsArginine VasopressinBenzazepinesClinical Trials as TopicDrug Evaluation, PreclinicalHeart FailureHumansHyponatremiaReceptors, VasopressinSodium Potassium Chloride Symporter InhibitorsTolvaptan

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

20708094

Citation

Veeraveedu, Punniyakoti T., et al. "Arginine Vasopressin Receptor Antagonists (vaptans): Pharmacological Tools and Potential Therapeutic Agents." Drug Discovery Today, vol. 15, no. 19-20, 2010, pp. 826-41.
Veeraveedu PT, Palaniyandi SS, Yamaguchi K, et al. Arginine vasopressin receptor antagonists (vaptans): pharmacological tools and potential therapeutic agents. Drug Discov Today. 2010;15(19-20):826-41.
Veeraveedu, P. T., Palaniyandi, S. S., Yamaguchi, K., Komai, Y., Thandavarayan, R. A., Sukumaran, V., & Watanabe, K. (2010). Arginine vasopressin receptor antagonists (vaptans): pharmacological tools and potential therapeutic agents. Drug Discovery Today, 15(19-20), 826-41. https://doi.org/10.1016/j.drudis.2010.08.001
Veeraveedu PT, et al. Arginine Vasopressin Receptor Antagonists (vaptans): Pharmacological Tools and Potential Therapeutic Agents. Drug Discov Today. 2010;15(19-20):826-41. PubMed PMID: 20708094.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Arginine vasopressin receptor antagonists (vaptans): pharmacological tools and potential therapeutic agents. AU - Veeraveedu,Punniyakoti T, AU - Palaniyandi,Suresh S, AU - Yamaguchi,Ken'ichi, AU - Komai,Yutaka, AU - Thandavarayan,Rajarajan A, AU - Sukumaran,Vijayakumar, AU - Watanabe,Kenichi, Y1 - 2010/08/11/ PY - 2009/12/17/received PY - 2010/06/25/revised PY - 2010/08/02/accepted PY - 2010/8/17/entrez PY - 2010/8/17/pubmed PY - 2011/2/18/medline SP - 826 EP - 41 JF - Drug discovery today JO - Drug Discov Today VL - 15 IS - 19-20 N2 - Arginine vasopressin (AVP) attracted attention as a potentially important neurohormonal mediator of the heart failure (HF) syndrome and hyponatremic states in humans because AVP influences renal handling of free water, vasoconstriction and myocyte biology through activation of V₂ and V₁(a) receptors. Current research is exploring V₂- and dual V₁(a)/V₂ receptor antagonism for the treatment of hyponatremia, as well as for the congestion and edema associated with chronic HF, because vasopressin receptor antagonists might offer benefits in comparison with conventional loop diuretics. The purpose of this review is to update the current status of experimental and clinical studies with available vasopressin receptor antagonists (conivaptan and tolvaptan) and their potential role in the treatment of HF and hyponatremia of multiple causes. SN - 1878-5832 UR - https://www.unboundmedicine.com/medline/citation/20708094/Arginine_vasopressin_receptor_antagonists__vaptans_:_pharmacological_tools_and_potential_therapeutic_agents_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1359-6446(10)00259-X DB - PRIME DP - Unbound Medicine ER -